OncoCyte Corp Company Profile (AMEX:OCX)

About OncoCyte Corp (AMEX:OCX)

OncoCyte Corp logoOncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. Its initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It offers diagnostic tests for lung, breast and bladder cancer.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: AMEX:OCX
  • CUSIP: N/A
  • Web: www.oncocyte.com/
Average Prices:
  • 50 Day Moving Avg: $6.26
  • 200 Day Moving Avg: $6.26
  • 52 Week Range: $3.75 - $7.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.22
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.19 per share
  • Price / Book: 34.74
Profitability:
  • EBIDTA: ($13,320,000.00)
  • Return on Equity: -211.74%
  • Return on Assets: -111.72%
Misc:
  • Average Volume: 47,057 shs.
  • Short Ratio: 5.79
 

Frequently Asked Questions for OncoCyte Corp (AMEX:OCX)

What is OncoCyte Corp's stock symbol?

OncoCyte Corp trades on the AMEX under the ticker symbol "OCX."

Where is OncoCyte Corp's stock going? Where will OncoCyte Corp's stock price be in 2017?

2 equities research analysts have issued 12 month price targets for OncoCyte Corp's shares. Their predictions range from $7.75 to $7.75. On average, they expect OncoCyte Corp's stock price to reach $7.75 in the next twelve months. View Analyst Ratings for OncoCyte Corp.

Who are some of OncoCyte Corp's key competitors?

How do I buy OncoCyte Corp stock?

Shares of OncoCyte Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OncoCyte Corp's stock price today?

One share of OncoCyte Corp stock can currently be purchased for approximately $6.60.


MarketBeat Community Rating for OncoCyte Corp (AMEX OCX)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  35 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  66
MarketBeat's community ratings are surveys of what our community members think about OncoCyte Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for OncoCyte Corp (AMEX:OCX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.75

Analysts' Ratings History for OncoCyte Corp (AMEX:OCX)
Show:
DateFirmActionRatingPrice TargetDetails
5/23/2017Chardan CapitalBoost Price TargetBuy$6.50 -> $7.75View Rating Details
1/30/2017Canaccord GenuityReiterated RatingBuyView Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for OncoCyte Corp (AMEX:OCX)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for OncoCyte Corp (AMEX:OCX)
2017 EPS Consensus Estimate: ($0.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.13)($0.13)($0.13)
Q2 20171($0.14)($0.14)($0.14)
Q3 20171($0.11)($0.11)($0.11)
Q1 20181($0.11)($0.11)($0.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for OncoCyte Corp (AMEX:OCX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for OncoCyte Corp (AMEX:OCX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for OncoCyte Corp (AMEX:OCX)
Latest Headlines for OncoCyte Corp (AMEX:OCX)
Source:
DateHeadline
finance.yahoo.com logoOncoCyte to Present Data from its Liquid Biopsy Breast Cancer Diagnostic Test at the San Antonio Breast Cancer Symposium
finance.yahoo.com - September 12 at 7:55 AM
feeds.benzinga.com logoOncoCyte Confirms Launch Plans for Lung Cancer Diagnostic Test; Reports Progress Toward CLIA Lab Licensing and Second Quarter 2017 Financial Results
feeds.benzinga.com - August 14 at 4:48 PM
americanbankingnews.com logoOncoCyte Corp (OCX) Cut to Sell at ValuEngine
www.americanbankingnews.com - July 28 at 11:02 PM
finance.yahoo.com logoOncoCyte to Report Second Quarter Financial Results on August 14, 2017
finance.yahoo.com - July 27 at 5:53 AM
americanbankingnews.com logoOncoCyte Corp (OCX) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - June 20 at 11:40 PM
americanbankingnews.com logoOncoCyte Corp (OCX) Price Target Raised to $7.75
www.americanbankingnews.com - May 23 at 11:48 PM
feeds.benzinga.com logoThe Next Steps For OncoCyte After Better-Than-Expected Data
feeds.benzinga.com - May 23 at 2:17 PM
feeds.benzinga.com logoOncoCyte Presents Positive Lung Cancer Blood Test Data at American Thoracic Society
feeds.benzinga.com - May 22 at 3:29 PM
americanbankingnews.com logoOncoCyte Corp (OCX) Upgraded at ValuEngine
www.americanbankingnews.com - May 16 at 3:27 PM
feeds.benzinga.com logoOncoCyte Executive to Address Next Generation Dx Summit on Successful Reimbursement Strategies for Diagnostic Tests
feeds.benzinga.com - May 9 at 7:49 AM
finance.yahoo.com logoOncoCyte Establishes Medical Advisory Committee to Enhance Development Strategy for Lung Cancer Diagnostics
finance.yahoo.com - May 4 at 7:10 PM
finance.yahoo.com logoOncoCyte Continues to Make Progress Towards Commercialization; Reports First Quarter 2017 Results
finance.yahoo.com - April 28 at 8:41 AM
seekingalpha.com logoOncoCyte (OCX) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 9 at 6:50 PM
finance.yahoo.com logoOncoCyte Corporation to Present at Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - March 1 at 10:24 AM
nasdaq.com logoOncoCyte Corporation Reports Fourth Quarter and Full Year 2016 Financial Results
www.nasdaq.com - February 27 at 5:44 PM
finance.yahoo.com logoOncoCyte Receives $2 Million in Proceeds from Early Exercise of Warrants
finance.yahoo.com - February 21 at 5:53 PM
finance.yahoo.com logoOncoCyte Reports First Quarter 2016 Financial Results
finance.yahoo.com - May 18 at 4:05 PM
biz.yahoo.com logoONCOCYTE CORP Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - May 16 at 6:41 PM
finance.yahoo.com logoOncoCyte to Report First Quarter Financial Results on May 18, 2016
finance.yahoo.com - May 12 at 7:00 AM
thestreet.com logoAnalysts Expect RSCO Will Reach $87
www.thestreet.com - May 6 at 3:58 PM
finance.yahoo.com logoOncoCyte’s Bladder Cancer Abstract to be Featured in a Poster Discussion Session at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - April 21 at 6:30 AM
finance.yahoo.com logoONCOCYTE CORP Financials
finance.yahoo.com - April 7 at 1:04 PM
finance.yahoo.com logoONCOCYTE CORP Financials
finance.yahoo.com - April 7 at 1:04 PM
finance.yahoo.com logo6:30 am OncoCyte and The Wistar Institute announce 'positive' results in the development of a blood-based lung cancer test
finance.yahoo.com - April 4 at 6:30 AM
finance.yahoo.com logoOncoCyte and The Wistar Institute Announce Positive Results in the Development of a Blood-based Lung Cancer Test
finance.yahoo.com - April 4 at 6:30 AM
biz.yahoo.com logoONCOCYTE CORP Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - March 30 at 8:11 AM
finance.yahoo.com logoOncoCyte Corporation Reports Full Year 2015 Financial Results
finance.yahoo.com - March 30 at 8:00 AM
thestreet.com logo10 Worst-Performing Small-Cap Stocks in 2016
www.thestreet.com - January 23 at 2:20 PM

Social

Social activity is not available for this stock.
This page was last updated on 9/26/2017 by MarketBeat.com Staff